|
|
Article: VentriPoint Diagnostics Ltd. Engages CHF Investor Relations and Reports Approval of Shares Issued to Directors and Consultants as Payment for Services.
- Article from:
- PR Newswire
- Article date:
- October 2, 2008
CopyrightCOPYRIGHT 2008 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SEATTLE, Oct. 2 /PRNewswire/ -- VentriPoint Diagnostics Ltd. ("VentriPoint") (TSX Venture: VPT) announced today that, subject to TSX Venture Exchange approval, it has retained CHF Investor Relations (Cavalcanti Hume Funfer Inc., "CHF"), Canada's only IR firm whose management team's combined experience possesses more than 80 years covering brokerage, trading, financial analysis, and investment sales, over and above their work in IR.
Joseph Ashley, VentriPoint's President and CEO, commented, "Our technology has the potential to become the standard for monitoring cardiac status. Backed by CHF Investor Relations, we will add depth and breadth to our investment ...